Prof David Gardner

Prof David Gardner

Scientific Director, Melbourne IVF, a member of Virtus Health

Prof David Gardner is Group Director of ART, Scientific Innovation and Research of Virtus Health, parent company of TasIVF.

Professor David Gardner is Group Director of ART, Scientific Innovation and Research of Virtus Health. 

He began his career after completing his postgraduate training in Embryology/Biochemistry at the University of York, UK. In 1987 David was awarded a PhD on the Nutrition and Metabolism of the Mammalian Preimplantation Embryo and became a Fellow of Cellular and Molecular Physiology at Harvard Medical School in 1988. In 1989 he moved to the Centre for Early Human Development, Monash Medical Centre. At Monash David worked on methods for the successful culture and diagnosis of human embryos conceived through IVF. It was in David’s laboratory that developed the system for human blastocyst culture.

In 1997 he moved back to the USA where he became the Scientific Director of the Colorado Centre for Reproductive Medicine in Denver, where he was the first in the world to introduce blastocyst culture and transfer as a clinical procedure. The Denver clinic became the most successful IVF unit in the USA.

David returned to Australia in 2007 to take up the position of Chair of Zoology at the University of Melbourne and soon became Head of the Department until the end of 2014. In 2015 he took up the position of Research Professor in the newly formed School of BioSciences.

David has authored nearly 300 publications, five of which are in the 100 most cited papers in reproductive medicine and biology. He is ranked number three in the world for impact in his field, is one of the most highly cited scientists in reproductive medicine. His Textbook on Assisted Reproduction, now in its 5th Edition, is the most widely used book in human IVF worldwide.

David was elected as a Fellow of the Australian Academy of Science in May 2017 and was the recipient the 2017 Distinguished Researcher Award by the American Society for Reproductive Medicine. He is currently the President of the Alpha (International Society of Scientists in Reproductive Medicine), and leads an active research team working on embryo physiology, new embryo culture systems, the development of embryo biomarkers, and blastocyst-uterine interactions.